Scribe Therapeutics

Scribe Therapeutics is a biotech company that develops and engineers new therapeutics based on CRISPR. The company’s first technology, called X-Editing (XE) molecules, are highly engineered CRISPR enzymes that provide combined aspects of greater efficacy, specificity, and deliverability than currently available CRISPR genome editing technology. It also a long-term, engineering approach that can help establish CRISPR-based therapies as a new standard of clinical care and expand access to groundbreaking treatments that will impact millions of lives.

Scribe Therapeutics is overcoming the limitations of current genome editing technologies by developing custom-engineered enzymes and delivery modalities as part of a proprietary, evergreen platform for CRISPR-based genetic medicine. The company built for exceptional specificity within the genome – enabling therapeutic precision and allele-specific targeting.

Scribe Therapeutics was founded in 2018 and is headquartered in Alameda, CA, USA.

Scribe Therapeutics headquartered in United States, North America, operates in the Biotechnology, Life Science, Therapeutics sector. The company focuses on Biotechnology and has secured $4.3B in funding across 36 round(s). With a team of 11-50 employees, Scribe Therapeutics is actively contributing to advancements in Biotechnology. Their latest funding round, Convertible Note - Scribe Therapeutics, raised $Unknown amount. Discover more about their projects, partnerships, and impact on our platform.